NCT04294147View on ClinicalTrials.gov

A Study of Gastrointestinal Emptying Time in Adult Participants With Migraine Before and After Start of a mAb CGRP Antagonist

PHASE4CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

October 6, 2020

Primary Completion Date

March 5, 2021

Study Completion Date

March 5, 2021

Conditions
Migraine
Interventions
DRUG

Galcanezumab

Administered SC

DRUG

Erenumab

Administered SC

Trial Locations (3)

90048

Clinical Research Institute LLC, Los Angeles

92660

Pharmacology Research Institute, Newport Beach

06708

CMR of Greater New Haven, Waterbury

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT04294147 - A Study of Gastrointestinal Emptying Time in Adult Participants With Migraine Before and After Start of a mAb CGRP Antagonist | Biotech Hunter | Biotech Hunter